Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Low-dose tamoxifen as effective as higher doses for breast cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 1029
Rating:

Prof Andrea De Censi - S.C. Oncologia Medica, Genoa, Italy

Prof Andrea De Censi speaks to ecancer at SABCS 2018 about the results of the phase III TAM-01 clinical trial, where low-dose tamoxifen was found to be safe and effective in reducing recurrence and new breast disease for patients with DCIS, LCIS and ADH.

He explains they found that a much lower dose of tamoxifen resulted in around the same reduction of recurrence than past results with much higher doses, with less side effects.

Prof De Censi concludes by saying the results of this study this opens the doors for a primary prevention trial for healthy at risk women.

Watch his press conference here.

Read more about this work here
 

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation